未经证实:已经报道了GBM的不同变体。上皮样胶质母细胞瘤(GBM-E),横纹肌GBM(GBM-R),小小区GBM(GBM-SC),巨细胞GBM(GBM-GC),具有神经外胚层分化的GBM(GBM-PNET)具有未知的行为。
UNASSIGNED:我们对这些罕见的GBM变异进行了系统评价和个体患者数据分析。我们搜索了PubMed,谷歌搜索,和Cochrane图书馆的合格研究,直到2016年7月1日以英语发表,并收集有关年龄的数据,性别,亚型和接受的治疗,无进展生存期(PFS),总生存率(OS)。社会科学统计软件包(SPSS)v16软件用于所有统计分析。
UNASSIGNED:我们检索了196例罕见GBM亚型患者的数据。在这些GBM-GC中最常见(51%),其次是GBM-R(19%),GBM-PNET(13%),GBM-SC(9%)和GBM-E(8%)。诊断时的中位年龄为38、40、43.5、69.5和18岁,分别。GBM-E的男性:女性比例为2:1,GBM-SC为1:3。大多数患者使用最大安全的切除术,然后进行辅助局部放疗。然而,6例GBM-PNET患者,GBM-E各3个,GBM-SC接受辅助颅脊髓放射。在接受化疗的88名患者中,64例接受替莫唑胺单独或含有替莫唑胺的联合化疗。整个队列的平均PFS和OS分别为9和16个月。在单变量分析中,与进行次全切除术的患者相比,进行粗全切除术的患者的PFS和OS明显更好[23vs.13个月(p-0.01)]。GBMPNET的中位操作系统,GBM-GC,GBM-SC,GBM-R和GBM-E分别为32、18.3、11、12和7.7个月,分别(P=0.001)。有趣的是,31.3%,37.8%的GBM-E患者,GBM-R有CSF播散。
UNASSIGNED:与未另作说明的GBM相比,罕见GBM变体的总体队列具有相等的生存期。然而,上皮样和横纹肌样GBM的存活率最差,三分之一显示CSF播散。
UNASSIGNED: Different variant of GBM has been reported viz. Epithelioid Glioblastoma (GBM-E), Rhabdoid GBM (GBM-R), Small cell GBM (GBM-SC), Giant cell GBM (GBM-GC), GBM with neuro ectodermal differentiation (GBM-PNET) with unknown behavior.
UNASSIGNED: We conducted a systematic
review and individual patient data analysis of these rare GBM variants. We searched PubMed, google search, and Cochrane library for eligible studies till July 1st 2016 published in English language and collected data regarding age, sex, subtype and treatment received, Progression Free Survival (PFS), Overall Survival (OS). Statistical Package for social sciences (SPSS) v16 software was used for all statistical analysis.
UNASSIGNED: We retrieved data of 196 patients with rare GBM subtypes. Among these GBM-GC is commonest (51%), followed by GBM-R (19%), GBM-PNET (13%), GBM-SC (9%) and GBM-E (8%). Median age at diagnosis was 38, 40, 43.5, 69.5 and 18 years, respectively. Male: female ratio was 2:1 for GBM-E, and 1:3 for GBM-SC. Maximal safe resection followed by adjuvant local radiation was used for most of the patients. However, 6 patients with GBM-PNET, 3 each of GBM-E, GBM-SC received adjuvant craniospinal radiation. Out of 88 patients who received chemotherapy, 64 received Temozolomide alone or combination chemotherapy containing Temozolomide. Median PFS and OS for the entire cohort were 9 and 16 months. In univariate analysis, patient with a Gross Total Resection had significantly better PFS and OS compared to those with a Sub Total Resection [23 vs. 13 months (p-0.01)]. Median OS for GBM PNET, GBM-GC, GBM-SC, GBM-R and GBM-E were 32, 18.3, 11, 12 and 7.7 months, respectively (P = 0.001). Interestingly, 31.3%, 37.8% of patients with GBM-E, GBM-R had CSF dissemination.
UNASSIGNED: Overall cohort of rarer GBM variant has equivalent survival compared to GBM not otherwise specified. However, epithelioid and Rhabdoid GBM has worst survival and one third shows CSF dissemination.